

OVERVIEW

- Cadila Healthcare Ltd. is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating , manufacturing, marketing and selling of finished active pharmaceutical ingredients ("APIs"), and consumer wellness products.
- Innovation is the backbone of the Company as it ensures business sustainability through continuous availability of new products for various businesses.

STRENGTHS

- Rank improved by 1 position; ranked 4th in the market
- Gained market share^ in anti-diabetic, anti-infective and nutraceuticals therapeutic areas on a Y-o-Y basis.
- 5 out of 7 brands seen double digit growth.
- Nutralite brand delivered a strong growth both in institutional and retail segments in Q1'22 despite lockdown in key markets
- Demand revival seen across channels with receding impact of 2nd wave and gradual opening of markets.

COVID 19 UPDATE

- Submitted the dossier to DCGI for an EUA of ZyCov-D vaccine with an interim Phase III CTs efficacy data for 2 mg.
- Phase III CTs data for 2 mg dose study of ZyCov-D vaccine also confirmed the safety for children in the age group of 12 to 18 years.
- Phase III CTs were carried out over 28000 subjects in more than 50 clinical sites spread across the country, reaffirming the vaccine's efficacy.

BUSINESS HIGHLIGHTS

- Business growth largely driven by base business, COVID portfolio and lower base effect of previous year
- Lipaglyn brand received "Brand Impact Award" from Indian Achievers forum.
- Connect with customers maintained during 2nd wave of COVID-19; all field employees were digitally equipped for their daily operations and customer connect.
- Digital transformation continued to be one of the key drivers of innovation and growth.
- Entered into a supply and commercialization agreement with TLC, to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis.

NEW PRODUCTS

- Zydus launches 'Virafin' for Treating Moderate Covid Patients
- Launched Virosshield Mouth Spray
- Liposomal Amphotericin B, A Critical Drug to Treat Black Fungus Or Mucormycosis
- Remdac is the most affordable Remdesivir at Rs. 899
- World's first Plasmid DNA vaccine, indigenously developed by Zydus for COVID-19 is awaiting approvals for Emergency Use Authorisation by the DCGI

SUMMARY OF FINANCIALS

- Revenue / turnover of CADILA HEALTHCARE LTD. Grew by 15%
- Net worth of the company has increased by 14.25 %
- EBITDA of the company has increased by 18.48 %
- CAPEX for the company stood at 265 cr.
- Liabilities of the company has decreased by 4.81 %
- PAT of the company grew by 29%
- EPS of the company stood at Rs.5.74

Disclaimer: The analysis is only for information purposes only. Please consult your financial advisor, agent, broker before acting on any information. We may or may not have positions in the stock. We would not be responsible for the profit/loss resulting from this analysis.

Growth Rates (Compound Annual)

	1 Yr	3 Yr	5 Yr	10yr
Revenue %	7.3	8.6	9.5	12.8
Operating Income %	27.7	4.5	5.2	11.2
Earnings/Share %	81.4	5.9	1.7	11.6
Dividends %	-	-	-	-
Book Value/Share %	25.2	14.1	17.9	19.6
Stock Total Return	18.3	14.3	4.8	13.3
Market +/-	-15	-1.8	-5.9	4.2

Valuation Analysis

	Current	5Yr Avg	Ind	Mkt.
Price/Earnings	22.6	26	28.7	15.2
Forward P/E	24.9	-	-	-
Price/Cash Flow	15.5	24.9	36.3	9.9
Price/Free Cash Flow	20.9	35.3	105	-
Dividend Yield %	0.7	1.0	0.7	2.8
Price/Book	3.9	5	4.2	2.1
Price/Sales	3.3	3.4	4.1	-

Profitability Analysis

	Current	5Yr Avg	Ind.	Mkt.
Return on Equity %	-	19	14.4	15.4
Return on Asset %	-	9	8.2	5.6
Gross Margin %	62.9	62	61	-
Operating Margin %	18	17.5	21.7	-
Net Margin %	14.8	13.8	14.4	-
Inventory Turns	-	2.0	1.6	-
Fixed Asset Turns	-	2.2	2.5	-

Financial Position (INR)

	03-20(Mil.)	03-21 (Mil.)
Cash	8,453	6,652
Inventories	27,890	32,362
Receivables	—	—
Current Assets	87,154	87,160
Fixed Assets	62,581	64,436
Intangibles	67,783	65,828
Total Assets	236,866	238,847
Payables	23,156	24,501
Short-Term Debt	47,718	39,740
Current Liabilities	82,694	78,613
Long-Term Debt	32,146	6,095
Total Liabilities	119,762	89,551
Total Equity	103,757	129,923

Source: Company filings & Analyst research